Biotechs up after All Ordinaries surge


By Tim Dean
Wednesday, 30 January, 2013


Life science stocks have enjoyed a boost alongside the broader share market, with stocks such as CSL (ASX:CSL) hitting historic highs.

The All Ordinaries has enjoyed its tenth straight daily increase, lifting the index 5.4% since the start of the calendar year, with biotech stocks rising with the tide.

Some, such as CSL (ASX:CSL), have reach all-time highs at $55.38, up 3.5% yesterday and another 0.6% today, a total increase of 2.74% since 1 January.

Cochlear (ASX:COH) saw a 0.8% bump in early trading yesterday, but slipped back to $81.50 as of around 2.30 pm this afternoon. However, its share price is a hefty 35% above where it was this time last year, having recovered from its recall slump.

Sirtex Medical (ASX:SRX) rose 68c since last Friday to $12.65, although it slipped slightly after midday back to $12.35. It has still pleased investors with an increase over the past several months.

The news about Mesoblast’s (ASX:MSB) clinical trial approval saw the company’s stock jump a few per cent to $5.78 after wallowing yesterday.

Starpharma (ASX:SPL) saw fairly heavy trading yesterday, but still languishes at $1.26, having failed to recover ground since the recent FDA setback.

Impedimed (ASX:IPD) was one of the few to drop yesterday, although it more than made up for it with a 20% increase today to reach 9.6c, although this is well below its price of 56c at this time last year.

Analysts have claimed that the lower interest rates have driven more money from savings into equities in search of higher returns, thus buoying the market. The ASX has now had its strongest run of increases since the global financial crisis.

Related News

Call for a strategic effort towards advanced manufacturing

Australia is in the position to secure a globally competitive, locally based advanced...

Digital health technology to manage respiratory diseases

Under a long-term supply agreement, Adherium will supply innovative new devices that AstraZeneca...

$40 million in financing to advance oral peptide drugs

Protagonist Therapeutics has announced the closing of a $40 million Series C financing, the...


  • All content Copyright © 2015 Westwick-Farrow Pty Ltd